Metal chaperones: a novel therapeutic strategy for brain injury?

Brain Inj. 2019;33(3):305-312. doi: 10.1080/02699052.2018.1552988. Epub 2018 Dec 3.

Abstract

Objective: This study sought to assess the potential efficacy of a novel class of metal chaperone on the outcomes in an animal model of a controlled cortical impact. This work was predicated on previous observations that this class of compound has exhibited neuroprotective potential in other models of aging and neurodegeneration.

Research design: The study employed a controlled cortical impact traumatic brain injury in three month old mice with subsequent behavioral and cellular assessments to determine therapeutic efficacy.

Methods: Cognitive (Y-maze) and motor assessments (Rotarod and Open Field) were employed to determine behavioral end points. Histological-based methods were utilized to assess neuronal integrity, astrocytosis, and lesion volume.

Outcomes: We demonstrate here that acute post-injury treatment with PBT2 (Prana Biotechnology) is sufficient to maintain neuronal integrity (evidenced by decreased lesion area and increased numbers of neurons; decreased astrocytosis was also present) and to normalize performance in cognitive testing (Y-maze). These effects occurred within days and were maintained for the entire duration of the study (26 days post-injury). These data support the further interrogation of the utility of metal chaperones for the treatment and/or prevention of the neuroanatomical, biochemical, and behavioral deficits that occur following brain injuries of different etiologies.

Keywords: Brain injury; cognition; metal chaperone; therapeutic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / pathology
  • Brain / pathology
  • Brain Injuries, Traumatic / drug therapy*
  • Brain Injuries, Traumatic / pathology
  • Brain Injuries, Traumatic / psychology
  • Chelating Agents / therapeutic use*
  • Cognition
  • Locomotion
  • Male
  • Maze Learning
  • Mice
  • Mice, Inbred C57BL
  • Neurons / pathology
  • Neuroprotective Agents / therapeutic use*
  • Psychomotor Performance / drug effects
  • Zinc / metabolism

Substances

  • Chelating Agents
  • Neuroprotective Agents
  • Zinc